Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 17;16(8):e67054.
doi: 10.7759/cureus.67054. eCollection 2024 Aug.

Acute Phase Peyronie's Disease: Where Do We Stand?

Affiliations
Review

Acute Phase Peyronie's Disease: Where Do We Stand?

Konstantinos Douroumis et al. Cureus. .

Abstract

Peyronie's disease (PD) is a common benign condition characterized by superficial fibrosis and scar formation at the tunica albuginea of the penis, eventually leading to penile curvature. It is believed that penile micro-traumas during intercourse and subsequent activation of inflammatory processes constitute the pathogenetic basis of the disease. Routinely, PD is divided into acute and chronic phases, with pain during erection or flaccid state being the hallmark of the former. Surgical intervention should be avoided during the acute phase, as the risk of recurrence or progression of penile deformity during this stage might affect the optimal outcomes of the procedure. During this stage, many conservative treatment options have been suggested, including oral, topical, and intralesional therapies, extracorporeal shock wave therapy (ESWT), and penile traction therapy (PTT). Currently, the optimal treatment consists of a combined treatment strategy with phosphodiesterase type 5 inhibitors (PDE5Is), ESWT for pain management, PTT, and intralesional therapies. Large, well-designed randomized controlled trials (RCTs) are necessary to further elucidate the most efficient treatment option for acute phase PD.

Keywords: acute phase; andrology; male sexual health; penile curvature; peyronie disease.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. A PRISMA flow diagram summarizing the selection process [57].
MEDLINE: Medical Literature Analysis and Retrieval System Online; Embase: Excerpta Medica database; CENTRAL: Cochrane Controlled Register of Trials; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

References

    1. Peyronie's disease development and management in diabetic men. Gianazza S, Belladelli F, Leni R, et al. Andrology. 2023;11:372–378. - PubMed
    1. The prevalence of Peyronie's disease: results of a large survey. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. BJU Int. 2001;88:727–730. - PubMed
    1. A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. Adv Urol. 2011;2011:282503. - PMC - PubMed
    1. The prevalence of Peyronie's disease in the United States: a population-based study. Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. PLoS One. 2016;11:0. - PMC - PubMed
    1. Peyronie’s disease: a review of etiology, diagnosis, and management. Bilgutay AN, Pastuszak AW. Curr Sex Health Rep. 2015;7:117–131. - PMC - PubMed

LinkOut - more resources